

In the Claims

1-69 (canceled).

70 (previously presented). An isolated monoclonal antibody or a fragment thereof that binds at least two different human inhibitory KIR receptor gene products, wherein said antibody or fragment thereof is capable of neutralizing KIR-mediated inhibition of natural killer (NK) cell cytotoxicity in NK cells expressing at least one of said two different human inhibitory KIR receptors, wherein said monoclonal antibody or fragment thereof is:

- a) the DF200 antibody produced by the hybridoma DF200, deposited as CNCM I-3224;
- b) a chimeric antibody comprising the variable region binding domains of the DF200 antibody;
- c) a humanized antibody comprising the CDRs of the DF200 antibody; or
- d) an Fab or F(ab')<sub>2</sub> fragment of any one of the antibodies set forth in a, b or c.

71 (previously presented). The isolated monoclonal antibody or a fragment thereof according to claim 70, wherein said antibody is the DF200 antibody produced by the hybridoma DF200, deposited as CNCM I-3224.

72 (previously presented). The isolated monoclonal antibody or a fragment thereof according to claim 70, wherein said fragment is an Fab or F(ab')<sub>2</sub> fragment of the DF200 antibody.

73 (previously presented). The isolated monoclonal antibody or a fragment thereof according to claim 70, wherein said antibody is a chimeric antibody comprising the variable region binding domains of the DF200 antibody.

74 (previously presented). The isolated monoclonal antibody or a fragment thereof according to claim 70, wherein said fragment is an Fab or F(ab')<sub>2</sub> fragment of said chimeric antibody.

75 (previously presented). The isolated monoclonal antibody or a fragment thereof according to claim 70, wherein said antibody is a humanized antibody comprising the CDRs of the DF200 antibody.

76 (previously presented). The isolated monoclonal antibody or a fragment thereof according to claim 70, wherein said fragment is an Fab or F(ab')<sub>2</sub> fragment of said humanized antibody.

77 (previously presented). The isolated monoclonal antibody or fragment thereof according to claim 70, wherein said monoclonal antibody or fragment thereof binds to KIR2DL1 and KIR2DL2/3.

78 (withdrawn-currently amended). An isolated monoclonal antibody or fragment thereof according to claim 70 conjugated or covalently bound to a toxin, detectable moiety, or solid support.

79 (previously presented). A composition comprising a pharmaceutically acceptable excipient and a monoclonal antibody or a fragment thereof that binds at least two different human inhibitory KIR receptor gene products, wherein said antibody or fragment thereof is capable of neutralizing KIR-mediated inhibition of NK cell cytotoxicity in NK cells expressing at least one of said two different human inhibitory KIR receptors, wherein said monoclonal antibody or fragment thereof is:

- a) the DF200 antibody produced by the hybridoma DF200, deposited as CNCM I-3224;
- b) a chimeric antibody comprising the variable region binding domains of the DF200 antibody;
- c) a humanized antibody comprising the CDRs of the DF200 antibody; or

d) an Fab or F(ab')<sub>2</sub> fragment of any one of the antibodies set forth in a, b or c.

80 (canceled).

81 (previously presented). The composition according to claim 79, wherein said antibody is the DF200 antibody produced by the hybridoma DF200, deposited as CNCM I-3224.

82 (canceled).

83 (previously presented). The composition according to claim 79, wherein said antibody is a chimeric antibody comprising the variable region binding domains of the DF200 antibody.

84 (previously presented). The composition according to claim 79, wherein said fragment is an Fab or F(ab')<sub>2</sub> fragment of said chimeric antibody.

85 (previously presented). The composition according to claim 79, wherein said antibody is a humanized antibody comprising the CDRs of the DF200 antibody.

86 (previously presented). The composition according to claim 79, wherein said fragment is an Fab or F(ab')<sub>2</sub> fragment of said humanized antibody.

87 (previously presented). The composition according to claim 79, wherein said monoclonal antibody or fragment thereof binds to KIR2DL1 and KIR2DL2/3.

88 (previously presented). An isolated monoclonal antibody or a fragment thereof that binds Killer Ig-Like Receptors (KIRs) KIR2DL1 and KIR2DL2/3, wherein said antibody or fragment thereof is capable of neutralizing KIR-mediated inhibition of NK cell cytotoxicity in NK cells expressing at least one of said KIR2DL1 and KIR2DL2/3.

89 (previously presented). A composition comprising a pharmaceutically acceptable excipient and an antibody according to claim 88.

90 (previously presented). An isolated monoclonal antibody or a fragment thereof that binds Killer Ig-Like Receptors (KIRs) KIR2DL1 and KIR2DL2/3, wherein said antibody or fragment thereof is capable of neutralizing KIR-mediated inhibition of NK cell cytotoxicity in NK cells expressing at least one of said KIR2DL1 and KIR2DL2/3, wherein said monoclonal antibody or fragment thereof competes for binding to said KIR2DL1 and/or KIR2DL2/3 on the surface of an NK cell with antibody DF200 produced by the hybridoma deposited as CNCM I-3224.

91 (previously presented). A composition comprising a pharmaceutically acceptable excipient and an antibody according to claim 90.